

Applicants: David M. Stern, et al.
U.S. Serial No.: 08/905,709
Filed: August 5, 1997
Page 2

Amendments to the claims

This listing of the claims will replace all prior versions and listings of claims in the application.

1. (Currently Amended) A method of inhibiting atherosclerosis in a subject suffering from hyperlipidemia which comprises administering to the subject a polypeptide ~~comprising the amino acid sequence of~~ which comprises a soluble extracellular portion of a receptor for advanced glycation endproduct (sRAGE) ~~or a derivative thereof~~ capable of inhibiting an interaction between amyloid- β peptide and receptor for advanced glycation endproduct (RAGE) in an amount effective to inhibit atherosclerosis in the subject.
2. (Original) The method of claim 1, wherein the subject is a mammal.
3. (Original) The method of claim 2, wherein the mammal is a human.
4. (Original) The method of claim 1, wherein the subject is a diabetic subject.
- 5-7. (Canceled)
8. (Original) The method of claim 1, wherein the subject has a glucose metabolism disorder.
9. (Original) The method of claim 1, wherein the subject is an

Applicants: David M. Stern, et al.
U.S. Serial No.: 08/905,709
Filed: August 5, 1997
Page 3

obese subject.

10-14. (Canceled)

15. (Original) The method of claim 1, further comprising administering to the subject a pharmaceutically acceptable carrier during the administration of the polypeptide.

16. (Previously Presented) The method of claim 1, wherein the administering is effected by intralesional, intraperitoneal, intramuscular or intravenous injection, infusion, liposome-mediated delivery, or topical, nasal, oral, ocular or otic delivery.

17-45. (Canceled)

46. (Previously Presented) The method of claim 1, wherein the polypeptide is admixed with a pharmaceutically acceptable carrier.